替米沙坦对高血压前期伴危险因素患者脉搏波传导速度和踝臂指数的影响  

Effects of Telmisatan on PWV and ABI in Patients with Pre-hypertension and Risk Factors

作　　者：吕雅萍[1] 袁琛[1] 马晓丽[1] 付金国[1] 肖娜[1] 张军[1] 

机构地区：[1]河北省沧州市中心医院心血管内五科,沧州061001

出　　处：《中国医药导刊》2013年第3期466-467,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨替米沙坦对高血压前期伴危险因素患者脉搏波传导速度(PWV)和踝臂指数(ABI)的影响。方法:165例高血压前期(SBP130mmHg≤SBP≤140mmHg和/或DBP85mmHg≤DBP≤90mmHg)伴危险因素患者,随机分为对照组80例和治疗组85例,治疗12个月后,观察治疗前后血压,PWV,ABI的变化。结果:与对照组相比,治疗组血压,PWV较治疗前明显降低,ABI增加。结论:替米沙坦可减少高血压前期伴危险因素的血压和PWV,增加ABI。Objective：To explore telmisartan prehypertension associated with patients with risk factors for pulse wave velocity（PWV） and ankle-brachial index（ABI）.Methods： Associated with risk factors for 165 patients with prehypertension（SBP130mmHg ≤ SBP ≤ 140mmHg and / or DBP85mmHg ≤ DBP ≤ 90 mmHg） were randomly divided into 85 cases of 80 cases of the control group and treatment group,after 12 months of treatment,blood pressure,PWV were observed before and after treatmentABI change.Results：Significantly reduced compared with control group,the blood pressure in the treatment group,the PWV in than before treatment,ABI increased.Conclusion：Telmisartan may reduce blood pressure and PWV prehypertension with risk factors increase the ABI.

关 键 词：高血压前期 替米沙坦 PWV ABI 

分 类 号：R544.1[医药卫生—心血管疾病]